In recent years, cell microencapsulation technology has advanced, mainly driven by recent developments in the use of stem cells or the optimization of biomaterials. Old challenges have been addressed from new perspectives, and systems developed and improved for decades are now being transferred to the market by novel start-ups and consolidated companies. These products are mainly intended for the treatment of diabetes mellitus (DM), but also cancer, central nervous system (CNS) disorders or lysosomal diseases, among others. In this review, we analyze the results obtained in clinical trials to date and define the global key players that will lead the cell microencapsulation market to bring this technology to the clinic in the future.

近年来，细胞微囊化技术取得了进步，主要受干细胞使用或生物材料优化的最新发展推动。旧的挑战已经从新的角度得到解决，几十年来开发和改进的系统现在正被新的初创企业和合并的公司转移到市场上。这些产品主要用于治疗糖尿病 (DM)，但也用于治疗癌症、中枢神经系统 (CNS) 疾病或溶酶体疾病等。在这篇综述中，我们分析了迄今为止在临床试验中获得的结果，并确定了未来将引领细胞微囊化市场将该技术带入临床的全球主要参与者。